A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors

To join this study, generally, you need to be at least 2 years old and have a confirmed diagnosis of PNH. You should also have been receiving treatment for your PNH, specifically eculizumab or ravulizumab, for at least 3 months before the study starts. Your blood test results (specifically for a protein called Lactate Dehydrogenase) should be within certain limits, and you need to be able to attend all study appointments and follow the instructions given.

There are also some reasons why you might not be able to join. For example, if you've recently had a bone marrow transplant or have certain types of bone marrow disorders, you wouldn't be eligible. The study also cannot include pregnant or breastfeeding individuals, or those planning to become pregnant during or shortly after the study. If you have active Hepatitis B or C, or have recently taken part in another experimental treatment study, that would also prevent you from joining.

If you decide to take part, you would receive either the new medicine, crovalimab, or the existing medicine, eculizumab. The study team would carefully monitor your health and how you respond to the treatment. This will involve regular visits to the clinic for check-ups, blood tests, and other medical assessments. The total duration of your participation in the study, including the treatment period and follow-up, would be fully explained to you before you agree to join. Women who could become pregnant would also need to agree to use effective contraception during the study and for a period afterwards.